Syros Pharmaceuticals, Inc.
SYRS
$0.032
-$0.0067-17.31%
OTC PK
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials
4/15/2025
-
PR Newswire
3/6/2025
-
Ticker Report
2/28/2025
-
The Fly
2/28/2025
-
TipRanks Financial Blog
2/28/2025
-
The Fly
2/28/2025
-
TipRanks Financial Blog
2/28/2025
-
Business Wire
2/28/2025
-
The Fly
2/20/2025
-
Ticker Report
2/14/2025
-
GuruFocus
2/12/2025
-
GuruFocus
2/3/2025
-
Ticker Report
1/30/2025
-
Ticker Report
1/26/2025
-
Ticker Report
1/11/2025
-
Ticker Report
1/2/2025
-
Ticker Report
1/1/2025
-
Ticker Report
12/24/2024
-
Ticker Report
12/16/2024
-
Ticker Report
12/13/2024
-
Ticker Report
12/7/2024
-
Ticker Report
12/5/2024
-
MarketBeat
12/1/2024
-
Ticker Report
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, October 31, 2024
Period Date
Monday, September 30, 2024
Next Filing
(est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
617 744 1340
Address
35 CambridgePark Drive
Cambridge, MA 02140
Cambridge, MA 02140
Country
Year Founded
Business Description
Sector
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective...
more